Table 3.

Multivariate analysis for overall survival.

Variables	ALL (N = 160)		HSPC (N = 52)		CRPC(N = 108)
	HR (95% CI)	p-Value	HR (95% CI)	p-Value	HR (95% CI)	p-Value
WHO performance status		0.242		0.167		0.391
0
1, 2
Cytoreductive extent
Minor cytoreduction	1	Ref	1	Ref	1	Ref
Major cytoreduction	0.56 (0.34–0.92)	0.022	0.18 (0.04–0.70)	0.014	0.61 (0.36–1.05)	0.075
Total cytoreduction	0.35 (0.19–0.66)	0.001	0.18 (0.05–0.65)	0.009	0.33 (0.15–0.73)	0.006
Metastatic burden (CHAARTED)		0.165		0.123		0.377
Low
High
Hormone sensitivity		0.754
CRPC
HSPC
PSA at radiotherapy initiation		0.002		0.715		0.011
>16.5 ng/ml*	1				1
≤ 16.5 ng/ml	0.51 (0.33–0.78)				0.52 (0.32–0.86)
PSA response		<0.001		0.053		0.003
Decline ≤ 50%	1				1
Decline > 50%	0.47 (0.30–0.72)				0.47 (0.28–0.78)

HSPC, hormone sensitive prostate cancer; CRPC, Castration-resistant prostate cancer; PSA, Prostate-specific antigen;

^*The optimal cutoff value of PSA at radiotherapy initiation defined by ROC curves. Bold values represent the p-values that are statistically significance.